SOLICITATION NOTICE
Q -- Analysis of global DNA Methylation in Leukocyte DNA and Renal Cell Cancer Risk
- Notice Date
- 8/25/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100209-TG
- Archive Date
- 9/24/2010
- Point of Contact
- Terry Galloway, Phone: 301-402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
gallowaytl@mail.nih.gov, cr214i@nih.gov
(gallowaytl@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Room 6068, Rockville, MD, 20852, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) plans to procure on a sole source basis the analysis of global DNA methylation in Leukocyte DNA and Renal Cell Cancer Risk including Alu and LINE-1 from Università degli Studi di Milano, Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health, Via San Barnaba 8, 20122 Milan, Italy. The supplies and services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541380 and the business size standard is $12 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. Renal cell cancer (RCC) comprises about 90% of histologically confirmed kidney cancer. Incidence rates of RCC have increased substantially in the United States since the 1970s, and the increases are faster among African Americans than Caucasians, resulting in higher incidence of this cancer among African Americans since the 1990s. Familial cases of RCC have been documented in relation to mutations in the VHL and a few other genes. In sporadic RCC cases, risk has been associated with genetic polomorphisms in genes involved in a number of RCC relevant pathways. Recently, epigenetic alternations have also been observed in tumor tissues of sporadic RCC. DNA methylation is an epigenetic mechanism that regulates chromosomal stability and gene expression, and is linked to both transcriptional silencing and activation. Abnormal DNA methylation patterns have been observed in many types of human tumors, since cells with abnormal DNA methylation acquire an overall gene expression pattern that favors proliferation and differentiation, leading to neoplastic transformation. Hypermethylation of the VHL gene has been shown in RCC tumors that are without mutation. Abnormal methylation patterns in RCC tumor tissues has been associated with tumor progression and poor prognosis. Recently, global hypomethylation in blood DNA has been linked to risk of developing some cancers, but this has not been studied in RCC. The contractor shall perform PCR amplification and pyrosequencing analysis for global DNA methylation analysis including Alu and LINE-1 in 2050 bisulfite-treated samples in triplicates per sample. The Center of Molecular and Genetic Epidemiology of the Università degli Studi di Milano, is a leading molecular epidemiology laboratory that has acquired the expertise and resources critical for conducting analyses of epigenetic changes in large epidemiologic studies. The Università degli Studi di Milano is the only institution worldwide to have pyrosequencing equipment for methylatin analysis dedicated exclusively to environmental epidemiology research. This lab previously has conducted leukocyte DNA methylation analysis in several NCI-led population-based studies in Europe, Asia, and the U.S. The conduction of the DNA methylation analyses in the same lab will allow NCI to simplify the control of laboratory operations and guarantee standardized quality control procedures. This will also enhance the comparability of results should NCI decides to conduct pooled analysis among the controls to examine host and environmental determinants of methylation status in the future. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 11:00 AM EST, on September 9, 2010. For further information, please contact Terry Galloway, Contract Specialist via electronic mail at gallowaytl@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-100209-TG on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100209-TG/listing.html)
- Record
- SN02254833-W 20100827/100825235730-6186bc48e8cbb91b600ef9bac52c02ef (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |